Ann Dermatol.  2022 Oct;34(5):321-330. 10.5021/ad.22.003.

Available Alternative Biologics and Disease Groups Influence Biologic Drug Survival in Patients with Psoriasis and Psoriatic Arthritis

  • 1Departments of Biostatistics , SMG-SNU Boramae Medical Center, Seoul, Korea
  • 2Departments of Dermatology, SMG-SNU Boramae Medical Center, Seoul, Korea
  • 3Department of Dermatology, Seoul National University College of Medicine, Seoul, Korea


Factors other than efficacy and safety could influence the survival of biologics in patients with psoriasis. Little is known about whether different disease groups affect drug survival of biologics or not.
This study aimed to investigate whether the availability of alternative biologics and disease groups could influence drug survival of biologics approved for psoriasis and psoriasis arthritis (PsA).
A nationwide population-based retrospective cohort study was conducted using the Health Insurance and Review Assessment data in Korea between January 2009 and August 2019.
The drug survival analysis included 5,634 biologic episodes. Ustekinumab was the most frequently prescribed drug (n=2,488, 44.2%). Multivariable time-dependent Cox regression analysis showed that higher age, female sex, no comorbidity, concomitant cyclosporine or acitretin use, biologic-experienced and use of tumor necrosis factor (TNF)-α inhibitors were predictors of drug discontinuation. PsA was a predictor of drug persistence, particularly for TNF-α inhibitors. Ustekinumab and adalimumab discontinuation significantly increased after introducing secukinumab and ustekinumab, respectively.
The availability of alternative biologics and disease groups affect biologic drug survival in patients with psoriasis and PsA.


Arthritis; psoriatic; Biological products; Interleukin inhibitors; Psoriasis; Survival analysis; Tumor necrosis factor inhibitors
Full Text Links
  • AD
export Copy
  • Twitter
  • Facebook
Similar articles
Copyright © 2023 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: